Surgery Partners, Inc. 10-K

Item 9A. Controls and Procedures Disclosure Controls and Procedures and Limitations on the Effectiveness of Controls An evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the 39 Table of Contents time periods specified in the SEC’s rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures conducted as of December 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective. Management’s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate "internal control over financial reporting" (as such term is defined in Rule 13a-15(f) under the Exchange Act) for the Company. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions and disposition of assets; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures are made only in accordance with management and board authorizations; and providing reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with GAAP. Because of the inherent limitations in any internal control, no matter how well designed, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025. The assessment was based on criteria established in the framework Internal Control-Integrated Framework (2013) , issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management, including the Chief Executive Officer and Chief Financial Officer, determined that our internal control over financial reporting was effective as of December 31, 2025. Ernst & Young LLP, the Company's independent registered public accounting firm, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2025. Their attestation report is included below in this Item 9A. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d‑15(d) of the Exchange Act that occurred during the quarter ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 40 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of Surgery Partners, Inc. Opinion on Internal Control Over Financial Reporting We have audited Surgery Partners, Inc.’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Surgery Partners, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows for the two years in the period ended December 31, 2025, and the related notes and our report dated March 2, 2026 expressed an unqualified opinion thereon. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Ernst & Young LLP Nashville, Tennessee March 2, 2026 41 Table of Contents Item 9B. Other Information From time to time, certain of our executive officers and directors have, and we expect they will in the future, enter into, amend and terminate written trading arrangements pursuant to Rule 10b5-1 of the Securities and Exchange Act of 1934 or otherwise. During the three months ended December 31, 2025, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K). Board Member Appointment On February 26, 2026, the Board of Directors of the Company appointed Lloyd Dean as a Class I director to fill the vacant directorship. As a Class I director, Mr. Dean’s term expires at the 2028 annual meeting of stockholders. The Board has determined that Mr. Dean is independent in accordance with Nasdaq listing standards. The Board has not appointed Mr. Dean to any committees of the Board, and it is unknown which committees of the Board Mr. Dean will serve on at this time. Mr. Dean’s compensation will be materially consistent with other non-employee directors of the Company, as described in the definitive proxy statement for the Company’s 2025 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 24, 2025. Additionally, Mr. Dean entered into the Company’s standard form of indemnification agreement. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable. 42 Table of Contents PART III Item 10. Directors, Executive Officers and Corporate Governance The information called for by Item 10 is incorporated herein by reference to the definitive Proxy Statement of the Company relating to the 2025 Annual Meeting of Stockholders (the "Definitive Proxy Statement"), which the Company intends to file within 120 days after the close of its fiscal year ended December 31, 2025. Item 11. Executive Compensation The information called for by Item 11 is incorporated herein by reference to the Definitive Proxy Statement. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information called for by Item 12 is incorporated herein by reference to the Definitive Proxy Statement. Item 13. Certain Relationships and Related Transactions, and Director Independence The information called for by Item 13 is incorporated herein by reference to the Definitive Proxy Statement. Item 14. Principal Accounting Fees and Services The information called for by Item 14 is incorporated herein by reference to the Definitive Proxy Statement. 43 Table of Contents PART IV Item 15. Exhibits and Financial Statement Schedules (a) Financial Statements and Financial Statement Schedules (1) Financial Statements Our Consolidated Financial Statements and Notes thereto are set forth starting on page F-1 of this Annual Report on Form 10-K. (2) Financial Statement Schedules All financial schedules have been omitted either because they are not applicable or because the required information is provided in our Consolidated Financial Statements and Notes thereto, starting on page F-1 of this Annual Report on Form 10-K. (b) Exhibits: No. Description 3.1 Amended and Restated Certificate of Incorporation of Surgery Partners, Inc., dated October 30, 2017 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 3, 2017). 3.2 Amended and Restated Bylaws of Surgery Partners, Inc., dated August 31, 2017 (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed September 1, 2017). 4.1 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated herein by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed March 1, 2023). 4.2 Indenture, dated April 10, 2024, among Surgery Center Holdings, Inc., the Guarantors from time to time party thereto and Wilmington Trust, National Association, as Trustee, including the Form of 7.250% Notes due 2032 attached as Exhibit A thereto (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed April 10, 2024). 4.3 First Supplemental Indenture, dated as of June 18, 2024, among Surgery Center Holdings, Inc., the Guarantors party thereto and Wilmington Trust, National Association, as Trustee, including the Form of 7.250% Notes due 2032 attached as Exhibit A thereto (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed December 16, 2025). 4.4 Second Supplemental Indenture, dated as of April 24, 2025, among Surgery Center Holdings, Inc., the Guarantors party thereto and Wilmington Trust, National Association, as Trustee, including the Form of 7.250% Notes due 2032 attached as Exhibit A thereto (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed December 16, 2025). 4.5 Third Supplemental Indenture, dated as of December 16, 2025, among Surgery Center Holdings, Inc., the Guarantors party thereto and Wilmington Trust, National Association, as Trustee, including the Form of 7.250% Notes due 2032 attached thereto (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed December 16, 2025). 10.1 Office Lease Agreement dated November 17, 2015 between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed March 11, 2016). 10.2 First Amendment to Lease Agreement, dated August 29, 2016, between Highwood Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed November 10, 2016). 10.3 Second Amendment to Lease Agreement, dated April 26, 2017, between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed May 10, 2017). 10.4 Amended and Restated Registration Rights Agreement by and among Surgery Partners, Inc., certain stockholders of Surgery Partners, Inc. and certain other parties thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed September 1, 2017). 10.5 Amendment and Joinder to Amended and Restated Registration Rights Agreement, dated December 22, 2022, by and among Surgery Partners, Inc., BCPE Seminole Holdings LP, BCPE Seminole Holdings III, L.P. and BCPE Seminole Holdings IV, L.P. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed December 22, 2022). 10.6 Form of TRA Waiver and Assignment Agreement (incorporated herein by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K filed March 16, 2018). 10.7 (a) Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.14 to Amendment No. 1 to the Company's Registration Statement on Form S-1, filed September 14, 2015). 10.8 (a) Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 (incorporated herein by reference as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed August 5, 2020). 10.9 (a) Surgery Partners, Inc. 2025 Omnibus Incentive Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed April 24, 2025). 10.10 (a) First Amendment to the Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed August 4, 2021). 10.11 (a) Surgery Partners, Inc. Cash Incentive Plan, as amended and restated effective January 1, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed August 5, 2020). 10.12 (a) Symbion, Inc. Supplemental Executive Retirement Plan, Effective May 1, 2005 (incorporated herein by reference to Exhibit 10.17 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015). 10.13 (a) Form of Non-Statutory Stock Option Agreement (incorporated herein by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015). 44 Table of Contents 10.14 (a) Form of Non-Employee Director Non-Statutory Stock Option Agreement (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015). 10.15 (a) Form of Restricted Stock Agreement (incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015). 10.16 (a) Form of Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed March 15, 2016). 10.17 (a) Form of Performance Stock Unit Award Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed July 5, 2016). 10.18 (a) Form of Non-Employee Director Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 3, 2017). 10.19 (a) Form of Stock-Settled Stock Appreciation Right Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed December 20, 2018). 10.20 (a) Surgery Partners, Inc. Employee Stock Purchase Plan (incorporated herein by reference to Appendix A of the Company's Proxy Statement filed on April 25, 2024). 10.21 (a) SP Management Services, Inc. Nonqualified Deferred Compensation Plan (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed August 6, 2024). 10.22 (a) Amended and Restated Employment Agreement, dated March 11, 2022, by and between Surgery Partners, Inc. and Jennifer Baldock (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed May 3, 2022). 10.23 (a) Employment Agreement, dated February 11, 2019, by and between Surgery Partners, Inc., Surgery Partners, LLC and J. Eric Evans (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 12, 2019). 10.24 (a) Amendment No. 1 to Employment Agreement by and between Surgery Partners, Inc., Surgery Partners, LLC and J. Eric Evans, dated January 13, 2020 (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 13, 2020). 10.25 (a) Employment Agreement, dated January 7, 2022, by and between Surgery Partners, Inc. and David T. Doherty (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 10, 2022). 10.26 (a) Employment Agreement, dated November 23, 2021, by and between Surgery Partners, Inc. and Marissa Brittenham (incorporated herein by reference to Exhibit 10.40 to the Company’s Annual Report on Form 10-K filed on March 1, 2022). 10.27 (a) Employment Agreement, dated July 25, 2022, by and between Surgery Partners, Inc. and Harrison Bane (incorporated herein by reference to Exhibit 10.41 to the Company's Annual Report on Form 10-K filed on March 1, 2023). 10.28 (a) Employment Agreement, dated October 27, 2025, by and between Surgery Partners, Inc. and Justin Oppenheimer (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 12, 2025). 10.29 Credit Agreement, dated as of December 19, 2023, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 20,2023). 10.30 First Amendment to the Credit Agreement, dated as of June 20, 2024, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., the Subsidiary Guarantors. Jefferies Finance LLC, and the other lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 20, 2024). 10.31 Second Amendment to the Credit Agreement, dated as of August 13, 2025, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., the Subsidiary Guarantors. Jefferies Finance LLC, and the other lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed August 13, 2025). 19 Insider Trading Policy (incorporated herein by reference to Exhibit 19 to the Company’s Annual Report on Form 10-K filed on March 7, 2025). 21 List of Subsidiaries of the Registrant. 23.1 Consent of Independent Registered Public Accounting Firm (Deloitte). 23.2 Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP). 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 97 Surgery Partners, Inc. Executive Compensation Recovery Policy (incorporated herein by reference to Exhibit 97 to the Company's Annual Report on Form 10-K filed on February 26, 2024). 101.INS Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 45 Table of Contents 104 The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, formatted in Inline XBRL (included in Exhibit 101). (a) Management Contract or Compensatory Plan or Arrangement. * Schedules and/or Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule or exhibit to the SEC upon request. Item 16. Form 10-K Summary None. 46 Table of Contents INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42 ) F- 2 Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34 ) F- 4 Consolidated Balance Sheets - December 31, 202 5 and 20 4 F- 1 Consolidated Statements of Operations - for the years ended December 31, 202 5 , 202 4 and 202 3 F- 2 Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, 202 5 , 202 4 and 202 3 F- 3 Consolidated Statements of Stockholders' Equity - for the years ended December 31, 202 5 , 202 4 and 202 3 F- 4 Consolidated Statements of Cash Flows - for the years ended December 31, 202 5 , 202 4 and 202 3 F- 5 Notes to Consolidated Financial Statements F- 6 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of Surgery Partners, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Surgery Partners, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. We also audited the disclosure of significant expenses and other segment items in Note 14 that have been disclosed for 2023 due to the adoption of ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures , and the recast of the segment disclosures in Note 14 to reflect one reportable segment. In our opinion, such disclosures are appropriate. However, we were not engaged to audit, review, or apply any procedures to the 2023 consolidated financial statements of the Company other than with respect to these disclosures and, accordingly, we do not express an opinion or any other form of assurance on the 2023 consolidated financial statements taken as a whole. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 2, 2026 expressed an unqualified opinion thereon. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. F-2 Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates. Revenue Recognition – Contractual Allowances and Implicit Price Concessions Description of the Matter For the year ended December 31, 2025, the Company’s revenues were $3.3 billion. As more fully described in Note 1 to the consolidated financial statements, the transaction price for revenues is determined based on gross charges for services provided, net of estimated contractual allowances and implicit price concessions (“price concessions”). Estimated price concessions are recognized at the time of services being performed and are generally based on historical experience of cash collections and write-offs for surgical hospitals. Auditing management’s estimate of surgical hospitals' price concessions was highly judgmental due to the significant data inputs and estimation uncertainty present in determining related amounts. How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the price concessions process for surgical hospitals, including controls over the review of estimated price concessions and the verification of the accuracy and completeness of the data used in the assessment. To test the adequacy of the estimated price concessions for surgical hospitals, our audit procedures included, among others, recalculating management’s model and assessing whether the recorded estimate was in accordance with their policy. We developed an independent estimate of price concessions using historical collections by payor and location and compared the independent estimate to the price concession estimate developed by management. For our independent estimate, we tested the underlying data related to the recognition of patient level charges and the subsequent activities, including cash collections and write-offs. We assessed the historical accuracy of management’s estimated price concessions as a source of potential corroborative or contrary evidence. We also considered industry, economic, and company factors to determine the appropriateness of the price concessions. /s/ Ernst & Young LLP We have served as the Company’s auditor since 2024. Nashville, Tennessee March 2, 2026 F-3 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Surgery Partners, Inc. Opinion on the Financial Statements We have audited, before the effects of the retrospective adjustments to the disclosure of significant expenses and other segment items in Note 14 to the consolidated financial statements that have been disclosed for 2023 due to the adoption of ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures , and the recast of the segment disclosures in Note 14 to reflect one reportable segment, the accompanying consolidated statements of operations, comprehensive income (loss), stockholders' equity, and cash flows, for the year ended December 31, 2023 and the related notes (collectively referred to as the "financial statements") (the 2023 financial statements before the effects of the retrospective adjustments to the disclosure of significant expenses and other segment items and the recast of the segment disclosures to reflect one reportable segment in Note 14 to the financial statements are not presented herein) of Surgery Partners, Inc. and subsidiaries (the "Company"). In our opinion, the 2023 financial statements, before the effects of the retrospective adjustments to the disclosure of significant expenses and other segment items and the recast of the segment disclosures to reflect one reportable segment in Note 14 to the financial statements, present fairly, in all material respects, the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America . We were not engaged to audit, review, or apply any procedures to the disclosure of significant expenses and other segment items or the recast of the segment disclosures to reflect one reportable segment in Note 14 to the financial statements, and accordingly, we do not express an opinion or any other form of assurance about whether such retrospective adjustments are appropriate and have been properly applied. Those retrospective adjustments were audited by the successor auditor. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ Deloitte & Touche LLP Nashville, Tennessee February 26, 2024 We began serving as the Company’s auditor in 2018. In 2024 we became the predecessor auditor. F-4 Table of Contents SURGERY PARTNERS, INC. CONSOLIDATED BALANCE SHEETS (Dollars in millions, except per share amounts) December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 239.9 $ 269.5 Accounts receivable 602.2 579.1 Inventories 96.6 88.4 Prepaid expenses 41.1 36.4 Other current assets 170.9 146.0 Total current assets 1,150.7 1,119.4 Property and equipment, net 1,153.4 1,088.3 Intangible assets, net 41.0 45.7 Goodwill 5,194.6 5,068.0 Investments in and advances to affiliates 234.0 215.4 Right-of-use operating lease assets 289.2 295.7 Other long-term assets 56.8 57.5 Total assets $ 8,119.7 $ 7,890.0 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 208.7 $ 208.7 Accrued payroll and benefits 64.9 60.4 Other current liabilities 242.6 253.9 Current maturities of long-term debt 99.3 101.4 Total current liabilities 615.5 624.4 Long-term debt, less current maturities 3,602.9 3,268.9 Right-of-use operating lease liabilities 279.9 292.1 Long-term deferred tax liabilities 53.4 39.2 Other long-term liabilities 41.2 30.2 Non-controlling interests—redeemable 395.5 438.8 Stockholders' equity: Preferred stock, $ 0.01 par value; shares authorized - 20,310,000 ; shares issued or outstanding - none — — Common stock, $ 0.01 par value; shares authorized - 300,000,000 ; shares issued and outstanding - 129,321,144 and 127,109,383 , respectively 1.3 1.3 Additional paid-in capital 2,540.6 2,520.9 Accumulated other comprehensive (loss) income ( 13.8 ) 4.8 Retained deficit ( 815.2 ) ( 737.3 ) Total Surgery Partners, Inc. stockholders' equity 1,712.9 1,789.7 Non-controlling interests—non-redeemable 1,418.4 1,406.7 Total stockholders' equity 3,131.3 3,196.4 Total liabilities and stockholders' equity $ 8,119.7 $ 7,890.0 See notes to unaudited consolidated financial statements. 1 Table of Contents SURGERY PARTNERS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in millions, except per share amounts; shares in thousands) Year Ended December 31, 2025 2024 2023 Revenues $ 3,308.7 $ 3,114.3 $ 2,743.3 Operating expenses: Salaries and benefits 971.0 907.5 793.8 Supplies 878.9 812.9 745.0 Professional and medical fees 404.5 357.1 296.8 Lease expense 87.9 89.5 84.9 Other operating expenses 201.4 201.7 175.3 Cost of revenues 2,543.7 2,368.7 2,095.8 General and administrative expenses 118.2 138.7 120.9 Depreciation and amortization 176.0 152.6 118.1 Transaction and integration costs 73.9 100.1 61.7 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 Equity in earnings of unconsolidated affiliates ( 22.9 ) ( 19.5 ) ( 14.2 ) Litigation settlements 7.3 ( 0.8 ) 10.6 Loss on debt extinguishment 1.3 5.1 15.5 Other income, net ( 8.7 ) ( 20.0 ) ( 7.5 ) 2,919.2 2,765.5 2,415.3 Operating income 389.5 348.8 328.0 Interest expense, net ( 272.6 ) ( 201.7 ) ( 193.0 ) Income before income taxes 116.9 147.1 135.0 Income tax (expense) benefit ( 18.0 ) ( 134.6 ) 0.3 Net income 98.9 12.5 135.3 Less: Net income attributable to non-controlling interests ( 176.8 ) ( 180.6 ) ( 147.2 ) Net loss attributable to Surgery Partners, Inc. $ ( 77.9 ) $ ( 168.1 ) $ ( 11.9 ) Net loss per share attributable to common stockholders: Basic $ ( 0.61 ) $ ( 1.33 ) $ ( 0.09 ) Diluted (1) $ ( 0.61 ) $ ( 1.33 ) $ ( 0.09 ) Weighted average common shares outstanding: Basic 127,209 126,122 125,613 Diluted (1) 127,209 126,122 125,613 (1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive. See notes to unaudited consolidated financial statements. 2 Table of Contents SURGERY PARTNERS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Dollars in millions) Year Ended December 31, 2025 2024 2023 Net income $ 98.9 $ 12.5 $ 135.3 Other comprehensive (loss) income, net of tax: Derivative activity, net of tax of $ 0 ( 18.6 ) ( 52.7 ) ( 18.7 ) Comprehensive income (loss) 80.3 ( 40.2 ) 116.6 Less: Comprehensive income attributable to non-controlling interests ( 176.8 ) ( 180.6 ) ( 147.2 ) Comprehensive loss attributable to Surgery Partners, Inc. $ ( 96.5 ) $ ( 220.8 ) $ ( 30.6 ) See notes to consolidated financial statements. 3 Table of Contents SURGERY PARTNERS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Dollars in millions; shares in thousands) Common Stock Additional Paid-in Capital Accumulated Other Comprehensive (Loss) Income Retained Deficit Non-Controlling Interests— Non-Redeemable Total Shares Amount Balance as of December 31, 2022 125,961 $ 1.3 $ 2,478.0 $ 76.2 $ ( 557.3 ) $ 942.7 $ 2,940.9 Net (loss) income — — — — ( 11.9 ) 109.4 97.5 Equity-based compensation 633 — 18.5 — — — 18.5 Other comprehensive loss — — — ( 18.7 ) — — ( 18.7 ) Acquisition and disposal of shares of non-controlling interests, net — — 1.1 — — 98.2 99.3 Distributions to non-controlling interests—non-redeemable holders — — — — — ( 103.0 ) ( 103.0 ) Balance as of December 31, 2023 126,594 1.3 2,497.6 57.5 ( 569.2 ) 1,047.3 3,034.5 Net (loss) income — — — — ( 168.1 ) 143.8 ( 24.3 ) Equity-based compensation 515 — 33.5 — — — 33.5 Other comprehensive loss — — — ( 52.7 ) — — ( 52.7 ) Acquisition and disposal of shares of non-controlling interests, net — — ( 10.2 ) — — 342.6 332.4 Distributions to non-controlling interests—non-redeemable holders — — — — — ( 127.0 ) ( 127.0 ) Balance as of December 31, 2024 127,109 1.3 2,520.9 4.8 ( 737.3 ) 1,406.7 3,196.4 Net (loss) income — — — — ( 77.9 ) 159.6 81.7 Equity-based compensation 2,212 — 26.2 — — — 26.2 Other comprehensive loss — — — ( 18.6 ) — — ( 18.6 ) Acquisition and disposal of shares of non-controlling interests, net — — ( 6.5 ) — — 31.6 25.1 Distributions to non-controlling interests—non-redeemable holders — — — — — ( 179.5 ) ( 179.5 ) Balance as of December 31, 2025 129,321 $ 1.3 $ 2,540.6 $ ( 13.8 ) $ ( 815.2 ) $ 1,418.4 $ 3,131.3 See notes to consolidated financial statements. 4 Table of Contents SURGERY PARTNERS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, dollars in millions) Year Ended December 31, 2025 2024 2023 Cash flows from operating activities: Net income $ 98.9 $ 12.5 $ 135.3 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 176.0 152.6 118.1 Non-cash lease expense 37.8 38.9 35.2 Non-cash interest expense, net 9.6 6.5 25.0 Equity-based compensation expense 14.8 33.3 17.7 Net loss on disposals, consolidations and deconsolidations 30.4 40.6 14.4 Loss on debt extinguishment 1.3 5.1 15.5 Deferred income taxes 16.7 131.5 ( 1.7 ) Equity in earnings of unconsolidated affiliates, net of distributions received ( 0.8 ) ( 2.0 ) ( 2.2 ) Changes in operating assets and liabilities, net of acquisitions and divestitures: Accounts receivable ( 53.8 ) ( 72.1 ) ( 47.2 ) Other operating assets and liabilities ( 56.6 ) ( 46.8 ) ( 16.3 ) Net cash provided by operating activities 274.3 300.1 293.8 Cash flows from investing activities: Purchases of property and equipment ( 78.7 ) ( 90.4 ) ( 88.8 ) Payments for acquisitions, net of cash acquired ( 162.1 ) ( 378.8 ) ( 80.0 ) Proceeds from disposals of facilities and other assets 46.5 2.6 25.8 Purchases of equity investments ( 13.3 ) ( 1.7 ) ( 50.3 ) Proceeds from sales of equity investments 1.5 4.6 1.4 Other investing activities ( 40.5 ) ( 24.8 ) ( 33.7 ) Net cash used in investing activities ( 246.6 ) ( 488.5 ) ( 225.6 ) Cash flows from financing activities: Principal payments on long-term debt ( 1,039.8 ) ( 1,279.3 ) ( 807.1 ) Borrowings of long-term debt 1,202.6 1,729.7 826.6 Payments of debt issuance costs ( 4.1 ) ( 14.9 ) ( 24.3 ) Distributions to non-controlling interest holders ( 226.0 ) ( 170.5 ) ( 146.1 ) Proceeds (payments) related to ownership transactions with non-controlling interest holders 0.6 9.6 8.2 Other financing activities 9.4 ( 12.6 ) ( 12.5 ) Net cash (used in) provided by financing activities ( 57.3 ) 262.0 ( 155.2 ) Net (decrease) increase in cash and cash equivalents ( 29.6 ) 73.6 ( 87.0 ) Cash and cash equivalents at beginning of period 269.5 195.9 282.9 Cash and cash equivalents at end of period $ 239.9 $ 269.5 $ 195.9 Supplemental cash flow information: Interest paid, net of interest income received 256.8 199.7 169.6 Cash paid for income taxes 1.2 1.6 1.4 Non-cash purchases of property and equipment 14.2 12.9 18.0 See notes to consolidated financial statements. 5 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. Organization and Summary of Accounting Policies Organization Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, gastroenterology, ophthalmology, and general surgery. Although some of the Company's surgical hospitals may include emergency departments, they are generally not equipped to handle a broad spectrum of patient needs, including critical and traumatic injuries. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company." As of December 31, 2025, the Company owned or operated a portfolio of 176 surgical facilities, comprised of 157 ASCs and 19 surgical hospitals in 30 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves. The Company owned a majority interest in 90 of these surgical facilities and consolidated 121 surgical facilities for financial reporting purposes. Basis of Presentation The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of revenue, accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. Revenues The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The following table presents a summary of revenues by service type as a percentage of total revenues: Year Ended December 31, 2025 2024 2023 Patient service revenues 97.5 % 98.1 % 98.4 % Other service revenues 2.5 % 1.9 % 1.6 % Total revenues 100.0 % 100.0 % 100.0 % Patient service revenues. This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. Because the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service. 6 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and implicit price concessions. The Company estimates its contractual adjustments and implicit price concessions based on contractual agreements, its discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments and implicit price concessions are recognized at the time of services being performed, with ASCs generally based on contractual agreements and surgical hospitals generally based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments and implicit price concessions are recorded in the period of change, with final adjustments, if any, typically at the time of payment. Several states utilize supplemental Medicaid reimbursement programs for the purpose of providing reimbursement to providers to increase base rates to the levels that Medicare would have paid for the same service or for payments that offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. We account for payments under these supplemental programs as variable consideration and estimate the amount using the most likely amount method. Reimbursement under these programs, including the recognition of variable consideration, is reflected in patient service revenues. Taxes or other program-related costs are reflected in other operating expenses. Other service revenues. Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets and other non-patient services. The management agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed. The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions): Year Ended December 31, 2025 2024 2023 Amount % Amount % Amount % Patient service revenues: Private insurance $ 1,687.2 52.3 % $ 1,634.2 53.5 % $ 1,418.6 52.5 % Government 1,380.3 42.8 % 1,256.8 41.1 % 1,128.1 41.8 % Self-pay 87.6 2.7 % 82.3 2.7 % 68.1 2.5 % Other (1) 71.2 2.2 % 81.1 2.7 % 85.6 3.2 % Total patient service revenues 3,226.3 100.0 % 3,054.4 100.0 % 2,700.4 100.0 % Other service revenues (2) 82.4 59.9 42.9 Total revenues $ 3,308.7 $ 3,114.3 $ 2,743.3 (1) Other is comprised of automobile liability, letters of protection and other payor types. (2) Includes amounts attributable to related parties of $ 19.8 million, $ 17.4 million and $ 18.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. Accounts Receivable Accounts receivable from third-party payors are recorded net of contractual allowances and implicit price concessions, which are estimated based on established fee schedules, relationships with payors, procedure statistics and other objective information including the historical trend of cash collections and contractual write-offs. The Company estimates its contractual adjustments and implicit price concessions based on contractual agreements, its discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments and implicit price concessions are recognized at the time of services being performed, with ASCs generally based on contractual agreements and surgical hospitals generally based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments and implicit price concessions are recorded in the period of change, with final adjustments, if any, typically at the time of payment. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical 7 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient’s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients. The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. Impairment of Long-Lived Assets, Goodwill and Intangible Assets The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The evaluation is performed at the lowest level of identifiable cash flow. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets." Derivative Instruments and Hedging Activities The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting. The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. Non-Controlling Interests The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows. The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. The fair value of non-controlling interests upon acquisition are determined based on certain assumptions, including Level 3 unobservable inputs. Estimates and assumptions include the projected timing and amount of future cash flows as well as discount rates reflecting inherent risk due to lack of control and marketability, among others. Non-Controlling Interests — Redeemable. Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively. In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners’ or physician minority members’, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. Management believes the likelihood of an event occurring that would trigger such purchases was remote as of December 31, 2025. The non-controlling interests — redeemable are reported outside of stockholders' equity in the consolidated balance sheets. 8 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS A summary of activity related to redeemable non-controlling interests for the years ended December 31, 2025 and 2024 is as follows (in millions): December 31, 2025 2024 Balance at beginning of period $ 438.8 $ 327.4 Net income attributable to non-controlling interests—redeemable 17.2 36.8 Acquisition and disposal of shares of non-controlling interests, net—redeemable ( 14.0 ) 118.1 Distributions to non-controlling interest —redeemable holders ( 46.5 ) ( 43.5 ) Balance at end of period $ 395.5 $ 438.8 Cash and Cash Equivalents The Company considers all highly liquid investments with remaining stated maturities of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions. Inventories Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method. Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless there is a deconsolidation where the investments are a result of the Company no longer having control of a previously controlled entity but still retaining a non-controlling interest. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary. Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued. A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions): Carrying Amount Fair Value December 31, December 31, 2025 2024 2025 2024 Senior secured term loan $ 1,374.4 $ 1,388.1 $ 1,379.6 $ 1,400.2 7.250 % senior unsecured notes due 2032 $ 1,225.0 $ 800.0 $ 1,237.3 $ 815.0 The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values. Variable Interest Entities The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, " Consolidation" . The Company has the power to direct the activities that most significantly impact a VIE's economic performance. 9 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of December 31, 2025, the Company's consolidated VIEs consisted of nine surgical facilities and 27 physician practices. The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December 31, 2025 and 2024, were $ 75.1 million and $ 87.0 million, respectively, and the total liabilities of the consolidated VIEs were $ 40.4 million and $ 55.0 million, respectively. Professional and General and Workers' Compensation Insurance The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention. The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures , which established new requirements for the categorization and disaggregation of information in the rate reconciliation as well as for disaggregation of income taxes paid. The Company adopted and prospectively applied ASU 2023-09 effective January 1, 2025 and there was no material impact on our consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 22-40): Disaggregation of Income Statement Expenses, which requires entities to provide enhanced disclosures related to certain expense categories included in income statement captions. The ASU aims to increase transparency and provide investors with more detailed information about the nature of expenses reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. The ASU is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact this ASU may have on its financial statements and related disclosures. In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging (Topic 815): Hedge Accounting Improvements , which amends certain aspects of the hedge accounting guidance in ASC 815, to more closely align hedge accounting with the economics of an entity’s risk management activities. The ASU provides guidance on five discrete topics, including a topic pertaining to cash flow hedges. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted and entities must apply the ASU prospectively for all hedging relationships as of the date of adoption. The Company is currently evaluating the impact this ASU may have on its financial statements and related disclosures. 2. Acquisitions, Disposals and Deconsolidations Acquisitions During the year ended December 31, 2025: • The Company acquired a controlling interest in 12 surgical facilities, several physician practices and other ancillary businesses for aggregate cash consideration of $ 162.1 million, net of cash acquired, and non-cash consideration of $ 2.3 million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $ 29.9 million and goodwill of $ 186.0 million. • The Company acquired a non-controlling interest in four surgical facilities for aggregate cash consideration of $ 16.2 million, a portion of which was deferred in accordance with the purchase agreements. These non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the consolidated balance sheets. During the year ended December 31, 2024: • The Company acquired a controlling interest in eight surgical facilities and several physician practices for aggregate cash consideration of $ 378.8 million, net of cash acquired, and non-cash consideration of $ 1.1 million, which consisted of a non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $ 478.9 million, goodwill of $ 767.7 million and investments and advances to affiliates of $ 44.6 million related to an acquired surgical facility accounted for as an equity method investment. 10 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS During the year ended December 31, 2023: • The Company acquired a controlling interest in five surgical facilities, four physician practices and an in-development de novo surgical facility for aggregate cash consideration of $ 55.5 million, net of cash acquired, and non-cash consideration of $ 1.3 million, which consisted of non-controlling interest in one of the Company's existing surgical facilities. In connection with these acquisitions, the Company preliminarily recognized non-controlling interests of $ 38.7 million and goodwill of $ 84.7 million. • The Company acquired a controlling interest in six surgical facilities and an in-development de novo surgical facility, which were previously accounted for as equity method investments, for aggregate cash consideration of $ 24.3 million, net of cash acquired. The Company also amended the operating agreement of a previously non-controlled surgical facility resulting in the Company obtaining a controlling interest in the facility. These transactions resulted in the consolidation of the previously non-consolidated entities. The previously held non-controlling interests were remeasured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data. The acquisition date fair value of the previously held non-controlling interests was $ 38.7 million. As a result of increasing its ownership interest, the Company recognized a net loss of $ 9.3 million included in net loss on disposals, consolidations and deconsolidations in the consolidated statements of operations for the year ended December 31, 2023. The net loss was determined based on the difference between the fair value of the Company's previously held non-controlling interests in the entities and the carrying values immediately prior to the transactions. In connection with the consolidation of these facilities, the Company preliminarily recognized non-controlling interests of $ 84.5 million and goodwill of $ 142.5 million. • The Company acquired non-controlling interests in five surgical facilities and two in-development de novo surgical facilities for aggregate cash consideration of $ 50.3 million. The non-controlling interests were accounted for as equity method investments and recorded as a component of investments in and advances to affiliates in the consolidated balance sheets. The Company also paid cash consideration of $ 21.0 million to acquire management rights from the prior management service provider related to four of the aforementioned surgical facilities. Management rights agreements are accounted for and recorded as a component of intangibles assets, net in the accompanying consolidated balance sheets. The cash paid to acquire the management rights is presented as a component of other investing activities on the consolidated statements of cash flows. Disposals and Deconsolidations During the year ended December 31, 2025: • The Company sold its controlling interests in three surgical facilities and one physician practice for aggregate net cash proceeds of $ 42.4 million. In connection with the transactions, the Company recognized a pre-tax net gain of $ 7.8 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2025. • The Company sold a portion of its interests in two surgical facilities for net cash proceeds of $ 4.1 million. As a result of these transactions, the Company no longer controlled the previously controlled surgical facilities but retained non-controlling interests, resulting in the deconsolidation of the previously consolidated entities. These transactions resulted in a pre-tax net gain on deconsolidation of $ 10.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2025. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Company’s retained interests in the entity and the carrying values of both the tangible and intangible assets and liabilities of the entity immediately prior to the transaction. During the year ended December 31, 2024: • The Company sold or otherwise disposed of its non-controlling interests in three surgical facilities, which were previously accounted for as a equity method investments, for cash proceeds of $ 2.6 million. In connection with these transactions, the Company recognized a pre-tax loss of $ 9.5 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2024. • The Company sold a portion of its interests in one surgical facility for net cash proceeds of $ 2.5 million. As a result of the transaction, the Company no longer controlled the previously controlled surgical facility but retained a non-controlling interest, resulting in the deconsolidation of the previously consolidated entity. This transaction resulted in a pretax net gain on deconsolidation of $ 2.7 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2024. The net gain was determined based on the difference between the net cash proceeds plus the fair value of the Company’s retained interests in the entity and the carrying values of both the tangible and intangible assets of the entity immediately prior to the transaction. • The Company sold or otherwise disposed of its controlling interests in nine surgical facilities and a physician practice for aggregate net cash proceeds of $ 5.4 million, a portion of which is deferred pursuant to the purchase agreements for such transactions. In connection with the transactions, the Company recognized a pre-tax net loss of $ 14.6 million, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2024. 11 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS • The Company recognized a pre-tax loss of $ 10.0 million related to an equity investment previously held at cost, which is included in net loss on disposals, consolidations and deconsolidations in the accompanying consolidated statements of operations for the year ended December 31, 2024. During the year ended December 31, 2023: • The Company sold its interests in six surgical facilities for aggregate net cash proceeds of $ 30.4 million, a portion of which was held in escrow pursuant to the purchase agreements for such transactions. In connection with these transactions, the Company recognized a pre-tax gain of $ 26.9 million included in net loss on disposals, consolidations and deconsolidations in the consolidated statements of operations for the year ended December 31, 2023. • The Company disposed of its non-controlling interests in a surgical facility and an in-development de novo surgical facility, which were previously accounted for as equity method investments, for cash proceeds of $ 1.5 million. In connection with these transactions, the Company recognized a pre-tax loss of $ 13.7 million included in net loss on disposals, consolidations and deconsolidations in the consolidated statements of operations for the year ended December 31, 2023. 3 . Property and Equipment Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings and building improvements, three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized. The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset. A summary of property and equipment follows (in millions): December 31, 2025 2024 Land $ 5.9 $ 9.7 Buildings and improvements 274.9 258.7 Furniture and equipment 33.1 32.7 Computer and software 130.1 120.0 Medical equipment 366.9 348.3 Right-of-use finance lease assets 944.5 818.1 Construction in progress 49.2 54.7 Property and equipment, at cost 1,804.6 1,642.2 Less: Accumulated depreciation ( 651.2 ) ( 553.9 ) Property and equipment, net $ 1,153.4 $ 1,088.3 Depreciation expense was $ 170.2 million, $ 144.8 million and $ 112.8 million for the years ended December 31, 2025, 2024 and 2023, respectively. 4 . Goodwill and Intangible Assets Goodwill Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company tests its goodwill for impairment in the fourth quarter of each year, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level. During 2025, the Company identified two reporting units, American Group and National Group. The Company compares the carrying value of the net assets of the reporting units to the estimated fair values. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. 12 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Based on the Company's annual goodwill impairment assessment performed as of October 1, 2025, it was determined that the estimated fair values of the reporting units were substantially in excess of their carrying values. A detailed evaluation of potential impairment indicators was performed, which specifically considered changes in interest rates, inflation risk and market volatility. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company’s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future. In 2025, 2024 and 2023, there were no non-cash impairment charges. A summary of the changes in the carrying amount of goodwill follows (in millions): December 31, 2025 2024 Balance at beginning of period $ 5,068.0 $ 4,326.0 Acquisitions, including post acquisition adjustments 176.4 757.2 Disposals and deconsolidations ( 49.8 ) ( 15.2 ) Balance at end of period $ 5,194.6 $ 5,068.0 A summary of the Company's acquisitions, disposals and deconsolidations for the years ended December 31, 2025 and 2024 is included in Note 2. "Acquisitions and Dispositions." Intangible Assets The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located and Medicare licenses. The Company tests these intangible assets for impairment in the fourth quarter of each year, or more frequently if certain indicators arise. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements and management rights agreements. Physician guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally two to four years . Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from two to five years for non-compete agreements and 15 years for the management rights agreements. A summary of the components of intangible assets follows (in millions): December 31, 2025 December 31, 2024 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Finite-lived intangible assets: Management rights agreements $ 53.2 $ ( 22.5 ) $ 30.7 $ 50.3 $ ( 18.7 ) $ 31.6 Other 30.2 ( 25.0 ) 5.2 30.1 ( 22.7 ) 7.4 Total finite-lived intangible assets 83.4 ( 47.5 ) 35.9 80.4 ( 41.4 ) 39.0 Indefinite-lived intangible assets 5.1 — 5.1 6.7 — 6.7 Total intangible assets $ 88.5 $ ( 47.5 ) $ 41.0 $ 87.1 $ ( 41.4 ) $ 45.7 Amortization expense for intangible assets was $ 6.1 million, $ 8.7 million and $ 7.6 million for of the years ended December 31, 2025, 2024 and 2023, respectively. 13 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions): 2026 $ 6.0 2027 5.4 2028 4.6 2029 3.8 2030 3.1 Thereafter 13.0 Total $ 35.9 5 . Long-Term Debt A summary of long-term debt follows (in millions): December 31, 2025 2024 Senior secured term loan (1) $ 1,374.4 $ 1,388.1 Senior secured revolving credit facility — 192.0 7.250 % senior unsecured notes due 2032 1,225.0 800.0 Notes payable and other secured loans 199.3 224.4 Finance lease obligations 935.5 798.7 Less: unamortized debt issuance costs and discounts ( 32.0 ) ( 32.9 ) Total debt 3,702.2 3,370.3 Less: current maturities 99.3 101.4 Total long-term debt $ 3,602.9 $ 3,268.9 (1) Includes unamortized fair value discount of $ 1.2 million and $ 1.4 million as of December 31, 2025 and 2024, respectively. Credit Facilities On December 19, 2023, the Company entered into a credit agreement (the “Credit Agreement”), which provided for a $ 1.4 billion senior secured term loan (the "Term Loan") and a $ 703.8 million revolving credit facility (the "Revolver" and, together with the Term Loan, the "Credit Facilities"). Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. The Term Loan matures on December 19, 2030. Prior to the First Amendment and Second Amendment, as defined below, the Term Loan bore interest at a rate per annum equal to (x) the forward-looking term rate based on Secured Overnight Financing Rate (“Term SOFR”) plus 3.50 % per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus, (ii) 0.50 % per annum above the federal funds effective rate and (iii) Term SOFR plus 1.00 % per annum, subject to a 1.00 % floor) (the “Base Rate”) plus 2.50 % per annum. The Term Loan amortizes in equal quarterly installments of 0.25 % of the aggregate original principal amount outstanding on the Term Loan, which commenced on the last business day of the fiscal quarter ending June 30, 2024. Subject to the right of reinvestment and certain other exceptions, the Term Loan requires mandatory prepayments upon the occurrence of certain events as defined in the Credit Agreement. Term Loan is also subject to an annual mandatory prepayment in an amount equal to a percentage of excess cash flow as determined based on the first lien net leverage ratio as of the last day of the applicable fiscal year. The Revolver matures on December 19, 2028. Interest on any loans drawn under the Revolver shall bear interest at a rate per annum equal to (x) Term SOFR plus 3.25 % per annum or (y) the Base Rate plus 2.25 % per annum. In addition, the Company is required to pay a commitment fee ranging from 0.50 % to 0.25 % per annum, depending on the Company’s first lien net leverage ratio, in respect of unused commitments under the Revolver. The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. As of December 31, 2025, the Company's availability on the Revolver was $ 692.8 million (including outstanding letters of credit of $ 11.0 million). With respect to the Revolver, the Company is required to comply with a maximum first lien net leverage ratio of 5.00 :1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is 14 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS drawn in an aggregate amount greater than 40 % of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors’ assets (subject to certain exceptions). The Credit Facilities includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Facilities also contain customary affirmative covenants and events of default. As of December 31, 2025, the Company was in compliance with the covenants contained in the Credit Agreement. In connection with the aforementioned financing transactions, the Company recorded debt issuance costs and discount of $ 34.5 million, and a debt extinguishment loss of $ 15.5 million, included in loss on debt extinguishment in the accompanying consolidated statement of operations for the year ended December 31, 2023. The loss includes the partial write-off of unamortized debt issuance costs and discounts related to the prior existing term loans, and a portion of debt issuance costs incurred with entering the Credit Facilities. Debt issuance costs related to a recognized debt liability are presented on the consolidated balance sheets as a direct reduction from the carrying value of the debt liability and amortized to interest expense using the effective interest method over the lives of the related debt agreements. First Amendment to Credit Agreement On June 20, 2024, the Company entered into a first amendment (the "First Amendment") to its Credit Agreement, which replaced or refinanced in full all the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the First Amendment) (the "2024 Refinancing Term Loans"). The 2024 Refinancing Term Loans mature on December 19, 2030. The 2024 Refinancing Term Loans bear interest at a rate per annum equal to (x) the forward-looking term rate based on Secured Overnight Financing Rate (“Term SOFR”) plus 2.75 % per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate plus 0.5 % per annum above the federal funds effective rate and (ii) Term SOFR plus 1.00 % per annum (which shall not be less than 1.00 %)) plus 1.75 % per annum. The 2024 Refinancing Term Loans amortize in equal quarterly installments of 0.25 % of the aggregate original principal amount of the 2024 Refinancing Term Loans. Voluntary prepayments of the 2024 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00 % call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the effective date of the First Amendment). In connection with the First Amendment, the Company recorded debt issuance costs and discount of $ 2.4 million, and a debt extinguishment loss of $ 2.3 million, which is included in loss on debt extinguishment in the accompanying consolidated statements of operations for the year ended December 31, 2024. The loss on debt extinguishment includes the partial write-off of unamortized debt issuance costs and discounts. Second Amendment to Credit Agreement On August 13, 2025, the Company entered into a second amendment (the "Second Amendment") to its Credit Agreement, which amends the Credit Agreement, dated as of December 19, 2023, and amended on June 20, 2024. The Second Amendment provides for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $ 1,383 million (the “2025 Refinancing Term Loans”), which 2025 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Second Amendment), and (ii) refinance in full all of the existing revolving credit commitments and outstanding revolving loans under the Credit Agreement (as in effect immediately prior to the Second Amendment), all as further set forth in the Second Amendment. The 2025 Refinancing Term Loans mature on December 19, 2030 and the refinanced revolving credit commitments and refinanced revolving loans mature on December 19, 2028. The 2025 Refinancing Loans shall bear interest at a rate per annum equal to (x) the forward-looking term rate based on Term SOFR plus 2.50 % per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) the federal funds effective rate plus 0.5 % per annum and (iii) Term SOFR plus 1.00 % per annum (which shall not be less than 1.00 %)) plus 1.50 % per annum. The 2025 Refinancing Term Loans amortize in equal quarterly installments of 0.25 % of the aggregate original principal amount of the 2025 Refinancing Term Loans (such amortization payments will commenced on the last business day of the fiscal quarter ending September 30, 2025). Voluntary prepayments of the 2025 Refinancing Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except a 1.00 % call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the Second Amendment Effective Date). In connection with the Second Amendment, the Company recorded debt issuance costs and discount of $ 1.6 million, and a debt extinguishment loss of $ 1.3 million which is included in loss on debt extinguishment in the accompanying consolidated statements of operations for the year ended December 31, 2025. The loss on debt extinguishment includes the partial write-off of unamortized debt issuance costs and discounts. 15 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 7.250 % Senior Unsecured Notes Due 2032 On April 10, 2024, the Company completed the issuance and sale of $ 800.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes"). The 2032 Notes were issued pursuant to an Indenture dated April 10, 2024 by and among Surgery Center Holdings, Inc., certain subsidiaries of Surgery Center Holdings, Inc., as guarantors, and Wilmington Trust, National Association, as trustee. The 2032 Notes bear interest at an annual rate of 7.250 % per year, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2024. Proceeds from the sale of the 2032 Notes were used (i) to redeem all of the outstanding 6.750 % senior unsecured notes due 2025 (the "2025 Notes") and the 10.000 % senior unsecured notes due 2027 (the "2027 Notes," together with the 2025 Notes, the "Existing Notes"), (ii) to pay accrued interest on the Existing Notes through, but not including, April 25, 2024, (iii) to pay related fees and expenses in connection with the offering of the 2032 Notes and redemption of the Existing Notes and (iv) for general corporate purposes, including to fund future acquisitions. In connection with this financing transaction, the Company recorded debt issuance costs and discount of $ 12.5 million, and a debt extinguishment loss of $ 2.8 million, which is included in loss on debt extinguishment in the accompanying consolidated statements of operations for the year ended December 31, 2024. On December 16, 2025, the Company completed the issuance and sale of $ 425.0 million in aggregate principal amount of senior unsecured notes due 2032 at 101.00 % of the principal cost. The notes were issued as part of the same series as the existing 2032 Unsecured Notes originally issued in April 2024, and have the same terms. In connection with the notes issuance, the Company recorded debt issuance costs, net of issuance premiums of $ 2.5 million. Proceeds from the sale of the $ 425.0 million 2032 Notes were used to (i) repay outstanding borrowings under the Revolver, (ii) pay fees and expenses incurred in connection with the offering of the 2032 Notes and (iii) for general corporate purposes, including potential future acquisitions. Other Debt Certain of the Company’s subsidiaries have outstanding indebtedness under notes payable and other secured loans, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations for which the Company is liable to various vendors for several property and equipment leases classified as finance leases. The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. Maturities A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December 31, 2025 follows (in millions): 2026 $ 99.3 2027 91.1 2028 83.1 2029 72.2 2030 1,382.8 Thereafter 2,006.9 Total $ 3,735.4 6. Leases The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited 16 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants. The Company also elected the accounting policy practical expedient to exclude leases with an initial term of twelve months or less from the balance sheet. Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability. The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions): Classification in Consolidated Balance Sheets December 31, 2025 December 31, 2024 Assets: Operating lease assets Right-of-use operating lease assets $ 289.2 $ 295.7 Finance lease assets Property and equipment, net of accumulated depreciation 740.4 655.6 Total leased assets $ 1,029.6 $ 951.3 Liabilities: Operating lease liabilities: Current Other current liabilities $ 42.7 $ 41.0 Long-term Right-of-use operating lease liabilities 279.9 292.1 Total operating lease liabilities 322.6 333.1 Finance lease liabilities: Current Current maturities of long-term debt 39.0 33.1 Long-term Long-term debt, less current maturities 896.5 765.6 Total finance lease liabilities 935.5 798.7 Total lease liabilities $ 1,258.1 $ 1,131.8 During the year ended December 31, 2025, the Company extended or otherwise modified the renewal terms of certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $ 36.6 million and $ 35.8 million, respectively, including the reclassification of existing operating lease liabilities and assets of $ 19.6 million and $ 18.5 million, respectively. The following table presents the weighted-average lease terms and discount rates at December 31, 2025 and 2024 (in millions): December 31, 2025 December 31, 2024 Operating Leases Finance Leases Operating Leases Finance Leases Weighted-average remaining lease term 10.8 years 19.6 years 9.8 years 19.2 years Weight average discount rate 7.5 % 7.2 % 7.9 % 8.1 % 17 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The following table presents the components of the Company's lease expense and their classification in the consolidated statements of operations (in millions): Year Ended December 31, 2025 2024 Operating lease costs $ 64.4 $ 65.8 Finance lease costs: Amortization of leased assets 81.9 62.1 Interest on lease liabilities 61.8 61.8 Total finance lease costs 143.7 123.9 Variable and short-term lease costs 24.4 24.5 Total lease costs $ 232.5 $ 214.2 During the years ended December 31, 2025 and 2024, the Company incurred lease costs of $ 25.1 million and $ 24.8 million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December 31, 2025 and 2024, the Company paid rent of $ 31.3 million and $ 25.7 million, respectively, under finance lease agreements with physician investors and a lessor who are related parties. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense. The following table presents supplemental cash flow information (in millions): Year Ended December 31, 2025 2024 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 61.3 $ 62.8 Operating cash outflows from finance leases $ 57.8 $ 59.1 Financing cash outflows from finance leases $ 39.2 $ 33.0 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 61.2 $ 132.3 Finance leases $ 31.5 $ 89.2 Future maturities of lease liabilities at December 31, 2025 are presented in the following table (in millions): Operating Leases Finance Leases 2026 $ 64.9 $ 102.5 2027 56.8 99.3 2028 46.9 94.4 2029 41.1 90.6 2030 35.9 87.5 Thereafter 226.0 1,439.8 Total lease payments 471.6 1,914.1 Less: imputed interest ( 149.0 ) ( 978.6 ) Total lease obligations $ 322.6 $ 935.5 7 . Derivatives and Hedging Activities The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2025 and 2024, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt. 18 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The key terms of interest rate swaps and interest rate caps outstanding are presented below: December 31, 2025 December 31, 2024 Description Effective Date Notional Amount (in millions) Status Notional Amount (in millions) Status Maturity Date Pay-fixed swap May 7, 2021 $ — Matured $ 435.0 Active March 31, 2025 Pay-fixed swap May 7, 2021 — Matured 330.0 Active March 31, 2025 Pay-fixed swap May 7, 2021 — Matured 435.0 Active March 31, 2025 Interest rate cap September 30, 2021 — Matured 143.6 Active March 31, 2025 Interest rate cap September 30, 2021 — Matured 8.2 Active March 31, 2025 Deferred premium cap March 31, 2025 393.0 Active 396.0 Active December 31, 2028 Deferred premium cap March 31, 2025 196.5 Active 198.0 Active December 31, 2028 Deferred premium cap March 31, 2025 393.0 Active 396.0 Active December 31, 2028 Deferred premium cap March 31, 2025 196.5 Active 198.0 Active December 31, 2028 Deferred premium cap March 31, 2025 196.5 Active 198.0 Active December 31, 2028 $ 1,375.5 $ 2,737.8 The Company had three interest rate swaps designated in cash flow hedging relationships, which matured on March 31, 2025. Prior to maturity, the interest rate swaps had a total notional amount of $ 1.2 billion and were pay-fixed, received 1-Month SOFR (subject to a minimum of 0.75 %). The Company had two interest rate caps designated in cash flow hedging relationships, which matured on March 31, 2025. Prior to maturity, the interest caps had a total notional amount of $ 151.8 million. Effective March 31, 2025, the Company had five deferred premium interest rate cap agreements. The deferred premium interest rate caps are designated in cash flow hedging relationships with a total notional amount of $ 1.4 billion. These financial instruments are designed to limit the Company's interest rate exposure on its term loan concurrent with the positions that matured on March 31, 2025. Prior to maturity, the pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps were considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. Within the Company’s consolidated balance sheets, the financing elements treated as debt instruments were carried at amortized cost and the embedded at-market derivatives were recorded at fair value. The fair value was determined using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The cash flows related to the portion treated as debt are classified as financing activities in the consolidated statements of cash flows while the portions that were treated as an at-market derivative are classified as operating activities. Within the Company’s consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the consolidated statements of cash flows. The fair value of the interest rate caps is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy. For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company’s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. Over the next 12 months, the Company estimates that an additional $ 5.5 million will be reclassified as an increase to interest expense. 19 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The following table presents the fair values of our derivatives and their location on the consolidated balance sheets (in millions): December 31, 2025 December 31, 2024 Assets Liabilities Assets Liabilities Derivatives in cash flow hedging relationships Interest rate caps (1) $ — $ — $ 1.1 $ — Interest rate swaps (1) — — 9.7 — Interest rate caps (2) — 13.8 — 6.1 Interest rate swaps (3) (4) — — — 3.5 Total $ — $ 13.8 $ 10.8 $ 9.6 (1) Amounts were included in other current assets on the consolidated balance sheets as of December 31, 2024. (2) Amounts were included in other long-term liabilities on the consolidated balance sheets as of December 31, 2025 and December 31, 2024. (3) Amounts were included in other current liabilities on the consolidated balance sheets as of December 31, 2024. (4) Amounts related to the financing component of the pay-fixed interest rate swaps. The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and consolidated statements of operations (in millions): Year Ended December 31, Location 2025 2024 2023 Derivatives not designated as hedging instruments Loss recognized in income Other income, net $ — $ — $ 0.6 Derivatives in cash flow hedging relationships (Loss) gain recognized in OCI (effective portion) $ ( 11.9 ) $ 4.3 $ 16.0 Gain reclassified from accumulated OCI into income (effective portion) (1) Interest expense, net ( 6.7 ) ( 57.0 ) ( 34.7 ) (1) Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $ 19.6 million for the year ended December 31, 2023. There were no corresponding amounts for the years ended December 31 2025 and 2024. 20 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 8. Earnings Per Share Basic and diluted earnings (loss) per share is calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings (loss) per share. A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share follows (dollars in millions, except per share amounts; shares in thousands): Year Ended December 31, 2025 2024 2023 Numerator: Net loss attributable to Surgery Partners, Inc. $ ( 77.9 ) $ ( 168.1 ) $ ( 11.9 ) Denominator: Weighted average common shares outstanding: Basic 127,209 126,122 125,613 Diluted (1) 127,209 126,122 125,613 Net loss per share attributable to common stockholders: Basic $ ( 0.61 ) $ ( 1.33 ) $ ( 0.09 ) Diluted (1) $ ( 0.61 ) $ ( 1.33 ) $ ( 0.09 ) Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive: Stock options 407 1,133 1,246 Restricted shares 512 372 263 (1) The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive. Share Repurchase Authorization On December 15, 2017, the Company's Board of Directors authorized a share repurchase program of up to $ 50.0 million of the Company's issued and outstanding common stock from time to time. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice. At December 31, 2025, the Company had $ 46.0 million of repurchase authorization available under the December 2017 authorization. The authorization does not obligate the Company to repurchase any shares, and the Company does not intend to make further repurchases. On February 26, 2026, our Board of Directors authorized a share repurchase program of up to $ 200.0 million. The share repurchase program authorized on February 26, 2026 replaced the previous program. 9. Income Taxes Income tax expense (benefit) is comprised of the following (in millions): Year Ended December 31, 2025 2024 2023 Current: Federal $ — $ — $ — State 1.1 3.1 1.4 Deferred: Federal 11.6 114.6 ( 1.5 ) State 5.3 16.9 ( 0.2 ) Total income tax expense (benefit) $ 18.0 $ 134.6 $ ( 0.3 ) 21 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax expense (benefit) computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% follows (in millions). The reconciling item of $ 43.0 million reverses the earnings attributable to the non-controlling interest as the Company is not responsible for the tax associated with those earnings. State taxes in Texas and Tennessee for 2025 made up the majority (greater than 50%) of the tax effect in this category. As of December 31, 2025 and December 31, 2024, the Company was in a cumulative three-year pre-tax loss position, which was considered significant negative evidence that could not be overcome by objective and verifiable positive evidence. Based on the weight of available evidence, the Company concluded that it was more likely than not that a portion of its net deferred tax assets will not be realized. Therefore, in accordance with ASC 740-10-30, the Company recorded a full valuation allowance, net of future reversing deferred tax liabilities, on its deferred tax assets to reflect the net realizable value as of the balance sheet dates. Below is tabular rate reconciliation pursuant to the disclosure requirements of ASU 2023-09 for the year ended December 31, 2025: Year Ended December 31, 2025 Amount Percent Tax expense at U.S. federal statutory rate $ 24.5 21.0 % State income tax, net of U.S. federal tax benefit 6.3 5.4 % Change in federal valuation allowance 18.1 15.5 % Net income attributable to non-controlling interests ( 43.0 ) ( 36.8 ) % Stock option compensation ( 2.7 ) ( 2.3 ) % Non-deductible compensation 4.1 3.5 % Differences related to divested facilities 1.9 1.6 % Other permanent items 1.0 0.9 % Tax return reconciling differences 7.5 6.4 % Other 0.3 0.3 % Total income tax expense (benefit) $ 18.0 15.4 % Below is a reconciliation of the statutory federal income tax expense and the Company's total income tax expense for the years ended December 31, 2024 and 2023: 2024 2023 Amount Amount Tax expense at U.S. federal statutory rate $ 30.8 $ 28.4 State income tax, net of U.S. federal tax benefit 19.9 0.9 Change in federal valuation allowance 115.4 21.5 Net income attributable to non-controlling interests ( 41.5 ) ( 30.9 ) Stock option compensation 5.5 0.1 Differences related to divested facilities ( 3.3 ) ( 18.9 ) Tax return reconciling differences 8.0 ( 1.0 ) Other ( 0.2 ) ( 0.4 ) Total income tax expense (benefit) $ 134.6 $ ( 0.3 ) 22 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The components of temporary differences and the approximate tax effects that give rise to the Company’s net deferred tax balance are as follows (in millions): December 31, 2025 2024 Deferred tax assets: Medical malpractice liability $ 5.0 $ 3.8 Accrued vacation and incentive compensation — 0.2 Net operating loss carryforwards 144.7 142.9 Allowance for bad debts 0.9 1.1 Capital loss carryforwards — 3.3 Section 163(j) interest 229.4 191.6 Interest rate derivative liability 3.6 2.5 Right of use liability 45.4 46.2 Software development costs — 2.1 Other deferred assets 11.2 9.9 Total gross deferred tax assets 440.2 403.6 Less: Valuation allowance ( 317.9 ) ( 284.7 ) Total deferred tax assets 122.3 118.9 Deferred tax liabilities: Depreciation on property and equipment ( 0.7 ) ( 1.3 ) Basis differences of partnerships and joint ventures ( 130.5 ) ( 106.7 ) Right of use asset ( 30.9 ) ( 36.8 ) Deferred financing costs ( 4.7 ) ( 5.3 ) Amortization of intangible assets ( 4.3 ) ( 3.1 ) Interest rate derivative asset — ( 2.9 ) Accrued vacation and incentive compensation ( 1.6 ) — Other deferred liabilities ( 3.0 ) ( 2.0 ) Total deferred tax liabilities ( 175.7 ) ( 158.1 ) Net deferred tax liabilities $ ( 53.4 ) $ ( 39.2 ) The Company had federal NOL carryforwards of $ 532.4 million as of December 31, 2025, of which $ 424.6 million expire between 2031 and 2037. The remaining federal NOL carryforwards, which were generated after 2017, do not expire. The Company had state NOL carryforwards of $ 657.1 million as of December 31, 2025, which expire between 2026 and 2045. The Company had federal Section 163(j) interest limitation carryforwards of $ 961.5 million as of December 31, 2025, which do not expire. The Company recorded a valuation allowance against deferred tax assets at December 31, 2025 and 2024 totaling $ 317.9 million and $ 284.7 million, respectively, which represents an increase of $ 33.2 million. The increase relates to recording valuation allowance on Section 163(j) interest carry-forward generated during 2025. The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2022 or state income tax examinations for years prior to 2021. The Company made income tax payments of $ 1.2 million, $ 1.6 million and $ 1.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. In each of these periods the income tax payments related to states in which the Company does not have a NOL to offset taxable income. During the years ended December 31, 2025, 2024 and 2023, the Company made no federal income tax payments due to utilization of its NOL carryforwards. The Company paid state income taxes of $ 1.0 million to Texas for the year ended December 31, 2025. 23 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December 31, 2025, 2024 and 2023 is as follows (in millions): December 31, 2025 2024 2023 Unrecognized tax benefits at beginning of year $ — $ — $ 0.1 Additions for tax provisions of the current year — — — Additions for acquired positions — — — Additions for tax positions of prior years — — — Reductions for tax positions of prior years — — ( 0.1 ) Reductions for statute of limitations expirations — — — Unrecognized tax benefits at end of year $ — $ — $ — The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For the years ended December 31, 2025 and 2024, the Company had no accrued interest and penalties related to uncertain tax positions. 10. Equity-Based Compensation On June 10, 2025, the Company's stockholders approved the Surgery Partners, Inc. 2025 Omnibus Incentive Plan ("2025 Omnibus Incentive Plan"), which replaced the Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 ("2015 Omnibus Incentive Plan"). Under the 2025 Omnibus Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December 31, 2025, 5,000,000 shares were authorized to be granted under the 2025 Omnibus Incentive Plan and 4,822,458 were available for future equity grants. Following approval of the 2025 Omnibus Incentive Plan, no further awards can be granted under the 2015 Omnibus Incentive Plan. However, awards granted prior to June 10, 2025 remain outstanding and continue to vest in accordance with their original terms. Shares subject to awards outstanding under the 2015 Omnibus Incentive Plan that are forfeited or expire are not available for reissuance. The terms of equity-based awards, including vesting conditions, are determined by the Compensation Committee and set forth in the applicable award agreements at the time of issuance. In general, vesting is contingent upon either a service, performance or market condition (or a combination thereof). Accelerated vesting for earned shares may occur upon certain terminating events, including a change in control of the Company. The Company measures the fair value of equity-based awards on the date of grant, with associated compensation costs recognized over the requisite service period, net of forfeitures as they occur. The Company’s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. Restricted and Performance Share-Based Awards During the years ended December 31, 2025 and 2024, the Company granted restricted stock awards ("RSAs") of 756,804 and 410,057 , respectively, to certain officers, employees and non-employee directors. In general, RSAs vest ratably over a one to three-year service period, contingent upon continued employment or service to the Company. During the years ended December 31, 2025 and 2024, the Company granted performance-based restricted stock units ("PSUs") of 750,335 and 399,745 , respectively, which were subject to the achievement of various performance conditions. The performance period for these PSUs is generally one year from the date of grant, with ratable vesting continuing for three years after the date of grant or a one-time cliff vesting. In addition to the achievement of the performance conditions, these PSUs are generally subject to the continuing service of the employee over the vesting periods. For certain PSUs awarded to officers of the Company, the number of shares payable at the end of the performance periods ranges from 0 % to 300 % of the targeted units based on the Company’s actual performance results and/or market conditions as compared to the targets. During the years ended December 31, 2025 and 2024, 503,708 and 123,742 of the PSUs previously granted were deemed to have been earned, respectively. 24 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Restricted and Performance Share-Based Activity A summary of non-vested restricted share-based activity for the years ended December 31, 2025, 2024, and 2023 follows: Unvested Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2022 995,413 $ 23.87 Granted/Earned 579,910 32.54 Forfeited/Cancelled ( 50,158 ) 35.14 Vested ( 794,315 ) 32.55 Outstanding at December 31, 2023 730,850 $ 38.10 Granted/Earned 533,799 30.85 Forfeited/Cancelled ( 48,002 ) 27.21 Vested ( 329,813 ) 30.81 Outstanding at December 31, 2024 886,834 $ 33.36 Granted/Earned 1,327,814 23.92 Forfeited/Cancelled ( 130,233 ) 21.83 Vested ( 876,167 ) 24.12 Outstanding at December 31, 2025 1,208,248 $ 26.95 Stock Options No stock options were granted during the years ended December 31, 2025, 2024 and 2023. Options to purchase shares are granted with an exercise price equal to the fair value of the Company’s common stock on the grant date. All of the outstanding stock options were exercisable as of December 31, 2025. Stock Option Activity A summary of stock option activity for the years ended December 31, 2025, 2024, and 2023 follows: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Outstanding at December 31, 2022 1,948,360 $ 12.69 5.9 Granted — Exercised ( 103,141 ) 12.92 4.0 Forfeited/Cancelled — Outstanding at December 31, 2023 1,845,219 $ 12.68 5.0 Granted — Exercised ( 29,859 ) 12.38 4.2 Forfeited/Cancelled — Outstanding at December 31, 2024 1,815,360 $ 12.68 4.0 Granted — Exercised ( 934,500 ) 11.32 3.3 Forfeited/Cancelled ( 4,015 ) 21.17 0.0 Outstanding at December 31, 2025 876,845 $ 12.12 3.3 Stock Appreciation Rights During the year ended December 31, 2025, 200,000 stock-settled stock appreciation right awards (the "SAR Awards") were exercised. These SAR Awards were granted on December 16, 2018. The SAR Awards had an exercise price of $ 12.90 . Fifty percent ( 50 %) of the SAR Awards vested in five equal annual installments on each of the first five anniversaries of the date of grant, generally subject to continued employment on each vesting date. Twenty-five percent ( 25 %) of the award vested based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $ 25.00 over a period of sixty ( 60 ) consecutive trading days, and twenty-five percent ( 25 %) of the award vested based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $ 35.00 over 25 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS a period of sixty ( 60 ) consecutive trading days, in each case, generally subject to continued employment on each vesting date. As of December 31, 2025, there were no SAR Awards outstanding. Other information pertaining to equity-based compensation At December 31, 2025, unrecognized compensation cost related to unvested shares was approximately $ 25.5 million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year. The Company records equity-based compensation expense to recognize the fair value of the restricted shares, stock options and SAR Awards granted over the relevant vesting period. The Company recorded equity-based compensation expense of $ 14.8 million, $ 33.3 million and $ 17.7 million for the years ended December 31, 2025, 2024 and 2023, respectively. 11. Employee Benefit Plans Surgery Partners 401(k) Plan The Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of five years . The Company's contributions were $ 18.0 million, $ 15.3 million and $ 12.6 million for the years ended December 31, 2025, 2024, and 2023, respectively. 12 . Other Current Liabilities A summary of other current liabilities was as follows (in millions): December 31, 2025 December 31, 2024 Right-of-use operating lease liabilities $ 42.7 $ 41.0 Cost report liabilities 4.7 21.3 Amounts due to patients and payors 46.6 31.8 Interest payable 19.5 13.4 Interest rate swaps — 3.5 Accrued expenses and other 129.1 142.9 Total $ 242.6 $ 253.9 13. Commitments and Contingencies Professional, General and Workers' Compensation and Cyber Liability Risks The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation and cyber liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of December 31, 2025 and 2024 were $ 23.9 million and $ 19.2 million, respectively. Expected insurance recoveries of $ 8.6 million and $ 9.6 million as of December 31, 2025 and 2024, respectively, are included as a component of other current assets and other long-term assets in the consolidated balance sheets. In May 2023, we experienced a cybersecurity incident that temporarily disrupted certain facilities in our Idaho market. We estimate that this incident had an adverse pre-tax impact of approximately $ 8 million during the year ended December 31, 2023. This estimate includes lost revenue from the associated business interruption and other related expenses. We have filed a claim with the insurance carrier related to this incident. Insurance recoveries of $ 6.5 million were recognized during each of the years ended December 31, 2024 and December 31, 2025. 26 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Laws and Regulations Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians. Acquired Facilities The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the federal physician self-referral law, or Stark Law, the statute commonly known as the federal Anti-Kickback statute, the federal False Claims Act, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party. The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable. Potential Physician Investor Liability A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected. 14 . Segment Reporting Segment information is prepared on the same basis that our Chief Executive Officer, who is our Chief Operating Decision Maker ("CODM"), manages our segments, evaluates financial results, and makes key operating decisions. We have one reportable segment: Surgical Facilities. The Surgical Facilities reportable segment is comprised of two operating segments, which we have aggregated to a single reportable segment in consideration of the aggregation criteria set forth in ASC 280. The Surgical Facilities reportable segment includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues primarily from contracts with patients in which the performance obligations are to provide health care services. The "All other" line item primarily consists of amounts attributable to the Company's corporate general and administrative functions. The Company defines its segments on the basis of the way in which its internally reported financial information is regularly reviewed by the CODM to assess performance and allocate resources. During the years ended December 31, 2025 and 2024, the operating segment previously defined as "Ancillary services" was included with Surgical Facilities based on changes in the operational management of our multi-specialty physician practices. The Company’s CODM uses Adjusted EBITDA to assess performance and allocate resources. The CODM considers budget-to-actual and actual versus prior period variances on a periodic basis as a means of assessing performance. The following segment information, including significant segment expenses, is presented in millions: 27 Table of Contents SURGERY PARTNERS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Year Ended December 31, 2025 2024 2023 Surgical Facilities Revenues $ 3,308.7 $ 3,114.3 $ 2,743.3 Less: Salaries and benefits 971.0 907.5 793.8 Supplies 878.9 812.9 745.0 Professional and medical fees 404.5 357.1 296.8 Lease expense 87.9 89.5 84.9 Other segment items (1) 340.2 337.3 288.5 2,682.5 2,504.3 2,209.0 Adjusted Surgical Facilities EBITDA $ 626.2 $ 610.0 $ 534.3 Reconciliation: Add back: Net income attributable to non-controlling interests ( 176.8 ) ( 180.6 ) ( 147.2 ) Unallocated amounts: General and administrative expenses 118.2 138.7 120.9 Transaction and integration costs 73.9 100.1 61.7 Other corporate expenses 45.4 50.4 52.8 Depreciation and amortization 176.0 152.6 118.1 Interest expense, net 272.6 201.7 193.0 Income before income taxes $ 116.9 $ 147.1 $ 135.0 (1) Other segment items includes equity in earnings of unconsolidated affiliates, net income attributable to non-controlling interests and other expenses, net. Year Ended December 31, 2025 2024 2023 Depreciation and amortization: Surgical Facilities $ 164.8 $ 138.9 $ 110.8 All other 11.2 13.7 7.3 Total depreciation and amortization expense $ 176.0 $ 152.6 $ 118.1 December 31, 2025 December 31, 2024 Assets: Surgical Facilities $ 7,643.9 $ 7,466.3 All other 475.8 423.7 Total assets $ 8,119.7 $ 7,890.0 Year Ended December 31, 2025 2024 2023 Cash purchases of property and equipment: Surgical Facilities $ 77.9 $ 86.6 $ 88.7 All other 0.8 3.8 0.1 Total cash purchases of property and equipment $ 78.7 $ 90.4 $ 88.8 28 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SURGERY PARTNERS, INC. By: /s/ J. Eric Evans J. Eric Evans Chief Executive Officer (Principal Executive Officer) Date: March 2, 2026 Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. SIGNATURES TITLE DATE Chief Executive Officer, Director (Principal Executive Officer) March 2, 2026 /s/ J. Eric Evans J. Eric Evans Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) March 2, 2026 /s/ David T. Doherty David T. Doherty Chairman of the Board March 2, 2026 /s/ Blair E. Hendrix Blair E. Hendrix Director March 2, 2026 /s/ T. Devin O'Reilly T. Devin O'Reilly Director March 2, 2026 /s/ Teresa DeLuca Teresa DeLuca Director March 2, 2026 /s/ John A. Deane John A. Deane Director March 2, 2026 /s/ Brent Turner Brent Turner Director March 2, 2026 /s/ Andrew Kaplan Andrew Kaplan Director March 2, 2026 /s/ Clifford G. Adlerz Clifford G. Adlerz Director March 2, 2026 /s/ Laura L. Forese Laura L. Forese Director March 2, 2026 Lloyd Dean